Home › Therapeutic areas › Oncology › Colorectal Cancer
Colorectal Cancer (27 companies)
Companies with an active program in Colorectal Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADAG | Adagene | Oncology | 1 | Phase 2 | $99.4M | 10 |
| AKTS | Aktis Oncology | Oncology | 1 | Phase 1 | $910M | 10 |
| AVBP | ArriVent BioPharma | Oncology | 1 | Phase 3 | $553M | 7 |
| BCAX | Bicara Therapeutics | Oncology | 1 | Phase 2 | $637M | 4 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | 2 | Phase 1 | $156M | 6 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $109M | 15 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $507M | 10 |
| CYDY | CytoDyn | NeurologyOncology | 1 | Phase 2 | $367M | 3 |
| CTMX | CytomX Therapeutics | Oncology | 1 | Phase 1 | $423M | 7 |
| ELTX | Elicio Therapeutics | Oncology | 1 | Phase 2 | $40.5M | 6 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $16.7B | 23 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $6.66B | 17 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 1 | Approved | $1.44B | 12 |
| INBX | Inhibrx Biosciences | Oncology | 1 | NDA Submitted | $1.10B | 6 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 1 | Phase 2 | $60.7M | 13 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $688M | 13 |
| LEGN | Legend Biotech | Oncology Rare | 1 | Approved | $3.12B | 17 |
| MAIA | MAIA Biotechnology | Oncology | 1 | Phase 3 | $77.2M | 8 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 2 | Phase 2 | $47.7M | 8 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.56B | 13 |
| ONCY | Oncolytics Biotech | Oncology | 1 | Phase 2 | $51.7M | 4 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $92.2M | 7 |
| RVMD | Revolution Medicines | Oncology | 2 | Approved | $35.2B | 11 |
| SMMT | Summit Therapeutics | Oncology | 1 | NDA Submitted | $8.53B | 6 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 1 | Approved | $822M | 7 |
| VSTM | Verastem | Oncology | 1 | Approved | $934M | 5 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.59B | 28 |
No companies match.